Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Relief Therapeutics Hldg Ag (OP: RLFTF )

5.685 +0.090 (+1.61%)
Streaming Delayed Price Updated: 11:16 AM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Relief Therapeutics Hldg Ag

< Previous 1 2 3 4 5 6 7 Next >
Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provisional Patent Application for Stable Compositions of Aviptadil Suitable for Human Use
GENEVA, SWITZERLAND / ACCESSWIRE / January 4, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic... 
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
Relief Therapeutics Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA
GENEVA, SWITZERLAND / ACCESSWIRE / January 3, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Relief Reports U.S. Collab. Partner Announces Filing Breakthrough Therapy Request for Aviptadil in Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
GENEVA, SWITZERLAND / ACCESSWIRE / December 30, 2021 /RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Relief Reports Successful Conclusion of Patent Examination Procedure for Patent Application Entitled, 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'
GENEVA, SWITZERLAND / ACCESSWIRE / December 28, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic... 
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Relief Therapeutics Files Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
GENEVA, SWITZERLAND / ACCESSWIRE / December 16, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), announced today that it has filed a Registration Statement on Form 20-F... 
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
Relief Reports that U.S. Collaboration Partner Announces New, Favorable Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
GENEVA, SWITZERLAND / ACCESSWIRE / December 15, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQBRLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients... 
From Relief Therapeutics Holdings AG
Via AccessWire
Epigenetics, Psychedelics and Stem Cell Therapy are Topics of the Life Sciences Virtual Investor Conference Launching This Thursday
Photo by Chris Montgomery on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
Relief Reports that its U.S. Collaboration Partner has Agreed with Hungarian Health Officials on a Pathway for Aviptadil
GENEVA, SWITZERLAND / ACCESSWIRE / December 10, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTC PINK:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Relief Therapeutics Announces Executive Changes
- Nermeen Varawalla, MD, PhD, MBA appointed Chief Medical Officer, replacing Gilles Della Corte, MD - Jeremy Meinen promoted to Chief Accounting Officer - Marco Marotta promoted to Chief Business... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Relief Reports U.S. Collaboration Partner Identifies Significantly Higher Likelihood of Surviving & Recovering from Critical COVID-19 in Aviptadil Treated Patients Previously Administered Remdesivir
GENEVA, SWITZERLAND / ACCESSWIRE / November 29, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTC PINK:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate
Relief Therapeutics Holding SA's (OTC: RLFTF) collaborating partner NRx Pharmaceuticals Inc (NASDAQ: NRXP) has announced that the FDA has denied... 
Via Benzinga
Exposures COVID-19 Product Safety
Relief Therapeutics and InveniAI Sign a Strategic Collaboration Agreement to Identify New Product Development Opportunities using Artificial Intelligence
GENEVA, SWITZERLAND / ACCESSWIRE / November 24, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), announced today that it has signed a collaboration agreement (the "... 
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence COVID-19 Intellectual Property
Relief Reports that its U.S. Collaboration Partner has Announced the U.S. Food and Drug Administration has Denied Breakthrough Designation for Aviptadil
GENEVA, SWITZERLAND / ACCESSWIRE / November 24, 2021 / RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Relief Therapeutics Launches Level 1 ADR Program in the United States
GENEVA, SWITZERLAND / ACCESSWIRE / November 18, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF) (" Relief "), announced today that its Form F-6 registration statement has become effective,... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Relief Reports that its U.S. Collaboration Partner has Announced it has Received a U.S. Food and Drug Administration Review of Aviptadil Manufacturing Information
GENEVA, SWITZERLAND / ACCESSWIRE / November 12, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Relief Provides Corporate Update and Outlines Plans to Advance its Diversified Portfolio of Pipeline Candidates, Including RLF-100(TM) (Aviptadil)
GENEVA, SWITZERLAND / ACCESSWIRE / November 11, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief... 
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
Relief Therapeutics Announces Transitions in Commercial Organization to Implement Next Phase of Corporate Development
- Anthony M. Kim Appointed Senior Vice President and Head of U.S. Commercial Operations - Seasoned Biotech Executive Brings Vast U.S. Commercial Launch Experience to Relief - European and United... 
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
NRx Pharma Stock Nosedives As FDA Strikes Off Its COVID-19 Drug Hopeful
The FDA has declined the emergency use authorization (EUA) for NRx Pharmaceuticals' (NASDAQ: NRXP) Zyesami (aviptadil). The Company is developing... 
Via Benzinga
Exposures COVID-19 Product Safety
Relief Reports U.S. Collaboration Partner's Emergency Use Authorization Request for ZYESAMI/RLF-100 (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure was Declined by U.S. FDA
GENEVA, SWITZERLAND / ACCESSWIRE / November 5, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Relief Therapeutics Takes First Step to Create an ADR Program in the United States by Filing a Form F-6 Registration Statement with the U.S. Securities and Exchange Commission
GENEVA, SWITZERLAND / ACCESSWIRE / November 3, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) ("Relief"), announced today that it has taken the first steps to establish a Level 1 American... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Relief Reports U.S. Collaboration Partner has Announced Favorable New Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
GENEVA, SWITZERLAND / ACCESSWIRE / November 3, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Relief Therapeutics' Subsidiary Posts Early Data For Nasal Spray COVID-19 Treatment
Relief Therapeutics Holding SA's (OTC: RLFTF) wholly-owned subsidiary, APR Applied Pharma Research SA, has reported interim results from its clinical trial of... 
Via Benzinga
Exposures COVID-19
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Positive Interim Data from Its Clinical Trial of Novel Nasal Spray Sentinox in SARS-CoV-2 Infected Patients
Results Confirm the Safety and Tolerability of Sentinox and Suggest It Could Be Effective in Reducing Time to Negativization in SARS-CoV-2 Infected Patients GENEVA, SWITZERLAND / ACCESSWIRE / October... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Relief Therapeutics Reports Two Publications of Positive Data on Nexodyn(R) AOS for Hard-to-Heal Ulcers
A Prospective Series on Wound Bed Preparation with Nexodyn(R) AOS and Standard of Care and a 32-Week Follow-Up Study Published in the Peer Reviewed Journal of Wound Care GENEVA, SWITZERLAND /... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Why NRx Pharmaceuticals Stock Is Tumbling Today
The drugmaker is being sued by Relief Therapeutics. 
Via The Motley Fool
Topics Lawsuit
Exposures Financial Legal
Relief Reports U.S. Collaboration Partner Announces Journal of Infectious Diseases and Treatment Publishes Positive Aviptadil Data in High Comorbidity Critical COVID-19 Patients w/ Respiratory Failure
GENEVA, SWITZERLAND / ACCESSWIRE / October 15, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Relief Reports that its U.S. Collaboration Partner has Announced Progress on Worldwide Commercial Scale Development of ZYESAMI(TM) (aviptadil)
GENEVA, SWITZERLAND / ACCESSWIRE / October 13, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Relief Therapeutics Announces Filing of Lawsuit Against its U.S. Collaboration Partner, NeuroRx, Inc. and its CEO, Dr. Jonathan Javitt, for RLF-100(TM) (Aviptadil)
Lawsuit alleges multiple breaches of Collaboration Agreement GENEVA, SWITZERLAND / ACCESSWIRE / October 7, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) ("Relief"), today announced that... 
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
Acer Therapeutics Stock Jumps As UCD Candidate Is Under FDA Review
The FDA has accepted for review Acer Therapeutics Inc (NASDAQ: ACER) and its partner, Relief Therapeutics Holding SA's (OTC: RLFTF) marketing... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.